EGFR and head and neck squamous cell carcinoma: This data served as the basis for a phase I clinical trial evaluating the safety of intratumorally administered ErbB-targeted CAR T cells (termed T4 immunotherapy) in a 3+3dose-escalationn study with or without the administration of lymphodepleting chemotherapy in subjects with HNSCC (NCT01818323) [103].